Cite
APA Citation
Passamonti, F., Palandri, F., Saydam, G., Callum, J., Devos, T., Guglielmelli, P., Vannucchi, A. M., Zor, E., Zuurman, M., Gilotti, G., Zhang, Y., & Griesshammer, M. (2022). ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet, 9(7), e480–e492. http://access.bl.uk/ark:/81055/vdc_100158012197.0x00000f